Morphocell is developing iPSC-derived engineered tissues to address severe liver disease, from the most acute forms of liver failure to debilitating metabolic disorders and chronic conditions affecting millions of adults and children worldwide. The Company is also working to leverage its unique manufacturing solutions and delivery methods to expand the indications for its engineered tissues beyond the liver and target severe deficiencies affecting other organs and systems.

​

​

​